Compare Viatris Inc (VTRS) vs State Street SPDR S&P Homebuilders ETF (XHB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Viatris Inc vs State Street SPDR S&P Homebuilders ETF — how do they compare? Viatris Inc trades at $17.62 (market cap $20.03B), while State Street SPDR S&P Homebuilders ETF trades at $95.02 (market cap $1.49B). The key difference: Viatris Inc is far larger — about 13.4× State Street SPDR S&P Homebuilders ETF's market cap, and Viatris Inc pays a 2.75% dividend while State Street SPDR S&P Homebuilders ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Viatris Inc for 57 Days and State Street SPDR S&P Homebuilders ETF for 33 Days on average.
| VTRS | XHB | |
|---|---|---|
Market Cap | $20.03B | $1.49B |
Volume | 14,109,977 | 2,445,587 |
Sector | Health | Broad Market / Factor |
52-Week High | $18.27 | $121.36 |
52-Week Low | $9.74 | $94.86 |
Typical Hold Time | 57 Days | 33 Days |
Enterprise Value | $32.15B | — |
Dividend Yield | 2.75% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Viatris (VTRS) trades at $17.625, up 0.77% with a bullish technical signal. The company shows mixed fundamentals with declining revenue from $16.3B in 2022 to $14.3B in 2025 and negative net income margins, though recent quarters have beaten EPS estimates. Positive cash flow trends and a $0.12 dividend signal financial stability. Analyst consensus is mixed with 38% buy ratings and a $22.17 price target suggesting 26% upside.
The outlook balances operational strength against profitability challenges. Investment appeal lies in value metrics (P/S 1.38), consistent earnings beats, and dividend yield, but risks include sustained negative margins, high debt, and competitive pressures. The stock's re-rating depends on margin improvement and pipeline execution.
XHB, the SPDR S&P Homebuilders ETF, trades at $94.65, down 0.25% on the day. Technical indicators are bearish, with moving averages signaling sell pressure and oscillators neutral. The ETF tracks the homebuilding sector, which faces headwinds from high mortgage rates but potential tailwinds from new housing affordability legislation and institutional interest.
The outlook for XHB is mixed, balancing sector-specific risks like rising rates against legislative support and valuation opportunities. Investment appeal hinges on a housing market recovery, with risks including economic sensitivity and inventory constraints. Sentiment is cautious but notes historical buying signals at current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →About State Street SPDR S&P Homebuilders ETF
XHB invests in the U.S. homebuilding industry and related sectors. It provides equal-weighted exposure to homebuilders, building products, and home improvement retailers like Home Depot, Lowe's, and Builders FirstSource.
Read more on XHB →
